Companies developing therapies with novel components like membrane proteins must navigate CMC development without established regulatory guidance. Unlike well-understood biologics like monoclonal antibodies, the lack of precedent in databases creates unique challenges for defining processes and satisfying regulatory bodies, requiring pioneers to set the standards.
Entos Pharmaceuticals' delivery platform uses a fusion-associated small transmembrane (FAST) protein. Unlike LNPs that rely on endosomal uptake and escape, this vehicle directly fuses with the cell membrane. The particle becomes part of the membrane, releasing its cargo directly into the cytosol, a more efficient and potentially less toxic delivery mechanism.
Unlike many biologics that can be scaled exponentially, membrane proteins often have inherent expression limitations. This means that scaling up production is a linear, rather than exponential, process. This fundamental constraint directly impacts CMC strategy, facility planning, and the overall cost of goods for therapies relying on these complex proteins.
Instead of engaging large, slow-moving CDMOs, startups can significantly cut early-phase manufacturing timelines by partnering with smaller, agile university-based GMP facilities. This approach allows for faster tech transfer and greater hands-on involvement from the startup's team, enabling them to compress year-long timelines into months.
The trade-off between speed and process robustness is a false dichotomy. The key is to design a robust process that includes predefined and validated "pause steps." These holding points allow for flexibility to handle unforeseen issues like mechanical failures without compromising the entire batch, thus enabling both speed and quality.